Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: The value of prostate cancer antigen 3 (PCA3), prostate health index (Phi) and sarcosine

Anticancer Research

Volumn 35, Issue 2, 2015, Pages 1017-1023

  Ferro, Matteo ^a   Lucarelli, Giuseppe ^b   Bruzzese, Dario ^c   Perdonà, Sisto ^d   Mazzarella, Claudia ^c   Perruolo, Giuseppe ^c   Marino, Ada ^c   Cosimato, Vincenzo ^c   Giorgio, Emilia ^c   Tagliamonte, Virginia ^c   Bottero, Danilo ^a   De Cobelli, Ottavio ^a   Terracciano, Daniela ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Urology and Kidney Transplantation Unit   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gleason score; PCA3; Phi; Sarcosine; Tumor stage; Tumor volume

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER PATIENT; CANCER SURGERY; COMPARATIVE STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATECTOMY; SURGICAL PATIENT; TUMOR VOLUME; URINALYSIS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ANTIGENS, NEOPLASM; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; SARCOSINE;

EID: 84922928584     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lazzeri M and Guazzoni G: Focal therapy meets prostate cancer. Lancet 376: 1036-1037, 2010.
2. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH and Mizrahi IA: A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185: 1650-1655, 2011.
3. Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A, Di Carlo A, Autorino R, di Lorenzo G, Buonerba C, Altieri V, Mariano A, Macchia V and Terracciano D: Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 413: 1274-1278, 2012.
4. Guazzoni G, Nava L, Lazzeri M, Scattoni V, Lughezzani G, Maccagnano C, Dorigatti F, Ceriotti F, Pontillo M, Bini V, Freschi M, Montorsi F and Rigatti P: Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting. Eur Urol 60: 214-222, 2011.
5. Lazzeri M, Haese A, de la Taille A, Palou Redorta J, McNicholas T, Lughezzani G, Scattoni V, Bini V, Freschi M, Sussman A, Ghaleh B, Le Corvoisier P, Alberola Bou J, Esquena Fernandez S, Graefen M and Guazzoni G: Serum Isoform [-2]proPSA Derivatives Significantly Improve Prediction of Prostate Cancer at Initial Biopsy in a Total PSA Range of 2-10 ng/ml: A Multicentric European Study. Eur Urol 63: 986-994, 2013.
6. Perdona S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, Perruolo G, Longo M, Spinelli R, Di Lorenzo G, Oliva A, De Sio M, Damiano R, Altieri V and Terracciano D: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73: 227-235, 2013.
7. Stephan C, Vincendeau S, Houlgatte A, Cammann H, Jung K and Semjonow A: Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59: 306-314, 2013.
8. Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V, Gadda GM, Bini V, Cestari A, Buffi NM, Freschi M, Rigatti P and Montorsi F: Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 61: 455-466, 2012.
9. Tallon L, Luangphakdy D, Ruffion A, Colombel M, Devonec M, Champetier D, Paparel P, Decaussin-Petrucci M, Perrin P and Vlaeminck-Guillem V: Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness. Int J Mol Sci 15: 13299-13316, 2014.
10. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, Forgues A, Robert G, Vacherot F, Loric S, Allory Y, Ruffion A and de la Taille A: The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 110: 43-49, 2012.
11. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S and McLeod DG: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180: 1975-1978; discussion 1978-1979, 2008.
12. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C and Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914, 2009.
13. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A and Chinnaiyan AM: The role of sarcosine metabolism in prostate cancer progression. Neoplasia 15: 491-501, 2013.
14. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Burgel H and Darte C: Pre-analytical in vitro stability of [-2]proPSA in blood and serum. Clin Biochem 43: 926-928, 2010.
15. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS and Rittenhouse H: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52: 1089-1095, 2006.
16. Guo W: A note on adaptive Bonferroni and Holm procedures under dependence. Biometrika 96: 1012-1018, 2009.
17. Vickers AJ and Elkin EB: Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26: 565-574, 2006.
18. Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M and Ditonno P: Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate 72: 1611-1621, 2012.
19. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F and de la Taille A: Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 59: 422-429, 2011.
20. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H and Babaian RJ: PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179: 1804-1809; discussion 1809-1810, 2008.
21. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budaus L, Fisch M, Huland H, Graefen M and Haese A: Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59: 96-105, 2011.
22. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B and van der Poel H: Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 60: 1045-1054, 2011.
23. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G and Jung K: Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 185: 706-711, 2011.
24. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M and Jung K: Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58: 12-18; discussion 20-11, 2010.
25. Epstein JI: Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 186: 790-797, 2011.
26. Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH and Schroder FH: Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Eur Urol 50: 475-482, 2006.
27. Russo GI, Cimino S, Castelli T, Favilla V, Urzi D, Veroux M, Madonia M and Morgia G: Percentage of cancer involvement in positive cores can predict unfavorable disease in men with lowrisk prostate cancer but eligible for the prostate cancer international: active surveillance criteria. Urol Oncol 32: 291-296, 2014.